World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2026
Volume: 5; Issue: 1
Page: 24-26

DIFFERENCE BETWEEN VACCINES AGAINST DNA VIRUSES AND RNA VIRUSES

Dr. Shankar Prasad Bhattacharya*

Associate Professor, Community Medicine, MJNMC Coochbehar, West Bengal, India.

Article Received: 11 November 2025 | | ***Article Revised: 2 December 2025*** | | ***Article Accepted: 22 December 2025***

***Corresponding Author: Dr. Shankar Prasad Bhattacharya**
Associate Professor, Community Medicine, Mjnmc Coochbehar, West Bengal, India.
DOI: https://doi.org/10.5281/zenodo.18107797

How to cite this Article: Dr. Shankar Prasad Bhattacharya (2026) DIFFERENCE BETWEEN VACCINES AGAINST DNA VIRUSES AND RNA VIRUSES. World Journal of Pharmaceutical Science and Research, 5(1), 24-26. https://doi.org/10.5281/zenodo.18107797

ABSTRACT

Vaccination remains the most effective public health intervention for preventing viral diseases. With advances in biotechnology, vaccines now use diverse platforms—ranging from traditional inactivated or live-attenuated viruses to modern nucleic acid vaccines such as DNA and mRNA. This paper highlights critical differences between vaccines developed for DNA viruses versus RNA viruses, focusing on vaccine development processes, immunogenicity, efficacy profiles, and post-vaccination surveillance, including adverse events. RNA virus vaccines, particularly mRNA-based platforms, have demonstrated unprecedented speed in development and strong immunogenic responses, as seen during the SARS-CoV-2 pandemic. DNA virus vaccine strategies involve distinct challenges related to delivery and nuclear entry but offer benefits of stability and storage. Post-vaccination surveillance plays a crucial role in identifying rare side effects and assessing long-term protection. Understanding these differences informs future vaccine design and public health strategies.

KEYWORDS: DNA virus, RNA virus, mRNA vaccine, DNA plasmid vaccine, Immunogenicity, Vaccine efficacy, Surveillance, Adverse events.

1. INTRODUCTION

Viruses are broadly categorized by their genomic material—DNA or RNA. Vaccine development against these categories involves unique scientific and logistical considerations due to differences in viral replication, mutation rates, and host immune interactions.

2. Vaccine Development[1,2]

2.1. RNA Virus Vaccines

RNA virus vaccines (e.g., SARS-CoV-2, influenza) have used newer platforms like messenger RNA (mRNA). These vaccines deliver genetic instructions—mRNA—to host cells, enabling cells to produce viral proteins that elicit immune responses without using live pathogens. mRNA vaccines bypass the need for viral culture and have rapid production timelines once the genetic sequence is known. The lipid nanoparticle systems protect mRNA and aid delivery into cells.

2.2. DNA Virus Vaccines

DNA vaccines use a plasmid carrying the gene encoding the antigen. Cells must take up the DNA and transport it into the nucleus for transcription into mRNA then translation into protein. This additional step can slow antigen production and sometimes requires delivery methods like electroporation. DNA vaccines are generally more stable and easier to store than RNA vaccines.

3. Immunogenicity

RNA Vaccines: Tend to generate strong immune responses, engaging both humoral (antibody) and cellular immunity due to efficient antigen expression in the cytoplasm. mRNA can be modified (e.g., using nucleoside modifications) to improve stability and reduce innate immune overreaction.

DNA Vaccines: Immunogenicity has historically been modest compared to RNA platforms due to inefficiencies in delivery and expression. However, optimization strategies (e.g., CpG motifs) and new delivery technology aim to enhance immune activation.

4. Efficacy

Vaccines against RNA viruses like SARS-CoV-2 showed high efficacy in large clinical trials, particularly mRNA vaccines exceeding 90% efficacy against symptomatic disease. This contrasts with many DNA vaccines, which have demonstrated good but variable efficacy in human trials and are less widely approved. DNA vaccines such as ZyCoV-D (targeting SARS-CoV-2) have shown effectiveness but typically lower than mRNA counterparts.[3,4]

5. Safety and Side Effects

5.1. RNA Vaccines

Common side effects include injection site pain, fatigue, and mild systemic symptoms. mRNA vaccines are non-infectious and do not integrate with host DNA, lowering genomic risk. Rare events such as myocarditis/pericarditis have been documented in surveillance programs but are uncommon.

5.2. DNA Vaccines

DNA vaccines are generally well-tolerated. One theoretical concern is the potential for genomic integration, although real-world evidence suggests it is extremely rare. Side effects tend to be mild and comparable to other non-replicating vaccines.[5,6]

6. Post-Vaccination Surveillance

Surveillance systems (e.g., VAERS, VigiBase) detect rare adverse events not seen in clinical trials. For RNA vaccines, ongoing monitoring has identified uncommon side effects such as myocarditis in young adults, leading to recommendations for risk mitigation. DNA vaccines are newer in widespread use, so long-term safety data are

expanding. Surveillance also assesses vaccine effectiveness in real-world settings and tracks waning immunity, especially where viral mutation rates are high.[7]

7. DISCUSSION

RNA virus vaccine platforms benefit from rapid design and strong immunogenic profiles, making them suitable for emerging pathogens with high mutation rates. DNA virus vaccine platforms offer logistical advantages like thermal stability but face challenges in delivery and immunogenicity. A growing portfolio of vaccine platforms, including viral vectors and protein subunits, complements nucleic acid strategies to cover a range of viral pathogens.

8. CONCLUSION

The comparative analysis highlights RNA vaccines' success in rapid deployment and high efficacy, particularly during the COVID-19 pandemic. DNA vaccines, while promising for their stability and safety, often elicit weaker immune responses and require optimized delivery. Continued surveillance remains essential to ensure safety and adapt vaccines to evolving viral threats.

REFERENCES

1. A comprehensive comparison of DNA and RNA vaccines — RNA / BOC Sciences.
2. COVID-19 Vaccines: An Overview of Different Platforms | MDPI.
3. Safety and Efficacy of Common Vaccines against COVID-19 — MDPI.
4. Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions — PubMed.
5. DNA vs mRNA vaccines explanation | Molecular Medicine.
6. Different types of vaccines | GSK and Vaccine Knowledge Project.
7. ZyCoV-D DNA vaccine information.